Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals

• Published in: The Lancet (British edition) Vol. 353; no. 9160; pp. 1243 - 1244
• Main Authors: Babl, Franz E, Regan, Anne Marie, Pelton, Stephen I
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 10-04-1999; Lancet; Elsevier Limited
• Subjects: Adipose Tissue - abnormalities; Adolescent; Anti-HIV Agents - adverse effects; Biological and medical sciences; Body fat; Child; Child, Preschool; Children & youth; Drug therapy; Drug toxicity and drugs side effects treatment; Female; HIV; HIV Infections - drug therapy; HIV Infections - pathology; HIV Protease Inhibitors - adverse effects; HIV-1; Human immunodeficiency virus; Humans; Male; Medical sciences; Pharmacology. Drug treatments; Prevalence; Proteinase inhibitors; Risk factors; Surveys and Questionnaires; Toxicity: skin, dermoskeleton; Human; Immunopathology; Skin disease; Toxicity; AIDS; Immune deficiency; Infection; Case study; Chemotherapy; Treatment; Viral disease; Antiviral; Female; Lipodystrophy; Adipose tissue disorders; Child; Protease inhibitor; Bibliographic review
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(98)05754-7

An increasing number of HIV-1-infected children are being given protease inhibitors, but little is known about the prevalence and risk factors of abnormal body-fat distribution in children on antiretrovirals. Babl et al discuss a study to discover more about this phenomenon.